Genomic Health
LIFE. CHANGING.

Investor Contact:
investors@genomichealth.com

Corporate Fact Sheet

Key Facts

(as of 3.31.17)

Employees: >840

NASDAQ Ticker: **GHDX**

Q117 Revenue: **$84.0M**, 4% year-over-year increase

Cash and Cash Equivalents & Short-term Marketable Securities: **$94.4M**

Shares Used in Computing Basic Net Income Per Share (3 months): **34.0M**

Management

Kimberly Popovits,
Chairman of the Board,
Chief Executive Officer & President

G. Bradley Cole,
Chief Operating Officer &
Chief Financial Officer

Steven Shak, M.D.,
Co-Founder, Chief Scientific Officer

Frederic Pla, Ph.D.,
Chief Business & Product Development Officer

Jim Vaughn, R.Ph.,
Chief Commercial Officer

Phil Febbo, M.D.,
Chief Medical Officer

Laura Leber,
Chief Communications Officer

Kim McEachron,
Chief People Officer

Jason W. Radford,
Chief Legal Officer & Secretary

Ellen Beasley, Ph.D.,
Senior Vice President,
Products and Services R&D

Jon Cassel, Ph.D.,
Senior Vice President, Operations

Mike Vedda,
Senior Vice President, Information Technology, Chief Information Officer

Genomic Health, Inc. is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. With its Oncotype IQ® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX® gene expression tests for breast, prostate, and colon cancer that have been used to guide treatment decisions for more than 750,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests with the recently launched Oncotype SEQ® Liquid Select™ in lung cancer and collaboration with Epic Sciences to commercialize the Oncotype DX AR-V7 Nucleus Detect™ test this year. The company is based in Redwood City, California with international headquarters in Geneva, Switzerland.

- For more information, please visit www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

Business Model

Genomic Health's business model is based on the belief that clinically validated standardized genomic tests, in its Oncotype IQ portfolio of tests, provide valuable information for patients, physicians and payors.

- For over a decade, Genomic Health has delivered on the promise of precision medicine by providing personalized information based on a patient's unique biology to help ensure they receive the right treatment at the right time, allowing many to avoid unnecessary treatments and their side effects.
- Our tests are commercially available through our clinical reference laboratory located in Redwood City, California, which is accredited under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and by the College of American Pathologists, or CAP. In addition, this laboratory is an ISO 15189:2012 Internationally-Recognized Accredited Laboratory for Clinical Testing.
- We now have prospective evidence from more than 63,000 patients demonstrating that the Oncotype DX Breast Recurrence Score® accurately predicts outcomes, including initial results from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx sponsored by the National Cancer Institute and published by *The New England Journal of Medicine*.
- We have a world-class commercial channel and successful track record in securing clinical guidelines and insurance coverage to provide physicians and patients with a trusted, single source for genomic tests; as well as online services that make it easy to interpret and share results with patients.
- Access to our tests enables personalized treatment decision-making and has saved the healthcare system more than 3.5 billion in the United States alone.[1]
- We will continue to expand the Oncotype IQ Genomic Intelligence Platform through our own internal research and development as well as strategic partnerships; all with the mission of delivering precision medicine to make cancer care smarter.

[1] Company estimation based on number of patients tested, chemotherapy reduction, health economics studies and treatment cost.

Investor Contact:
investors@genomichealth.com

Board of Directors

Julian Baker,
Managing Partner,
Lead Independent Director,
Baker Brothers Investments

Felix Baker, Ph.D.,
Managing Partner,
Baker Brothers Investments

Fred Cohen, M.D., D.Phil.,
Senior Advisor, TPG

Henry J. Fuchs, M.D.,
Executive Vice President &
Chief Medical Officer,
BioMarin Pharmaceutical Inc.

Ginger L. Graham,
Former President & Chief
Executive Officer, Amylin
Pharmaceuticals

Geoffrey M. Parker,
Chief Financial Officer and Senior
Vice President, Tricida, Inc.

Kimberly Popovits,
Chairman of the Board,
Chief Executive Officer &
President, Genomic Health, Inc.

First Quarter 2017 Highlights

- Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, issued a draft local coverage determination (LCD) for the Oncotype DX Genomic Prostate Score™ (GPS) expanding Medicare coverage to include qualified patients with favorable intermediate-risk prostate cancer throughout the United States.
- Presented results from four studies evaluating the clinical validation and utility of the GPS in the management of early-stage prostate cancer at the 2017 Genitourinary (GU) Cancers Symposium. Collectively, these new data highlight the test's ability to predict disease aggressiveness and refine risk stratification across National Comprehensive Cancer Network (NCCN) clinical risk groups.
- Presented results from a large multi-center clinical validation study that used a longitudinal patient database from Kaiser Permanente's Northern California region demonstrating that the GPS predicts 10-year risk of developing metastatic prostate cancer. Designated one of the 'Best Posters' at the 32nd Annual European Association of Urology (EAU) Congress, results highlight the expanded value of the test in assessing risk and long-term outcomes in newly diagnosed prostate cancer patients.
- Additional results from the Kaiser validation study confirmed that the GPS test is a strong independent predictor of prostate cancer-specific death and disease progression (metastases) at 10 years in men with localized prostate cancer across all NCCN clinical risk groups. These results were presented at the American Urological Association (AUA) 2017 Annual Meeting.
- Three additional Oncotype DX GPS studies were presented at AUA, including an analysis that prospectively validated the GPS test as an independent predictor of adverse pathology in men with localized prostate cancer. A separate AUA presentation that was published in *Urology* reinforced that the GPS test significantly increases use and persistence on active surveillance.
- The German Association of Gynecological Oncology's (AGO's) updated treatment guidelines reconfirm Oncotype DX with the highest 1A level of evidence and recognize it as the only multi-gene breast cancer test available to predict chemotherapy benefit for women with early-stage, hormone-receptor positive, HER2-negative invasive breast cancer.
- Established an agreement with an additional German public health insurance fund, covering 2.5 million lives, to begin offering Oncotype DX to early-stage breast cancer patients.
- Presented results at the 15th St. Gallen International Breast Cancer Conference from 15 Oncotype DX Breast Recurrence Score studies conducted in 12 countries that provide real-world evidence of the test's ability to change treatment decisions for breast cancer patients.
- The journal *Breast Cancer Research and Treatment* published results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry, which demonstrated that many node-positive breast cancer patients can avoid chemotherapy based on their Oncotype DX Breast Recurrence Score.
- The *Journal of Surgical Oncology* published results from a multicenter trial, which demonstrated that the Oncotype DX Breast Recurrence Score can guide neoadjuvant therapy to help facilitate breast-conserving surgery for hormone receptor-positive breast cancer patients.
- Received acceptance to present eight Oncotype DX studies at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in June.